Whey Protein Lycosome Formulation Improves Vascular Functions and Plasma Lipids with Reduction of Markers of Inflammation and Oxidative Stress in Prehypertension

Table 2

Changes in lipid profile in prehypertensive patients treated with whey protein and lycopene formulations.

Product	TC	TG	LDL	HDL
	in mg/dL	in mg/dL	in mg/dL	in mg/dL
WP baseline after 1 month (n = 10)	215 ± 9.9	147 ± 10.1	133 ± 13.2	40.7 ± 0.6
	222 ± 11.3	151 ± 12.3	132 ± 11.5	40.9 ± 0.7
	P > 0.05	P > 0.05	P > 0.05	P > 0.05
Lycopene baseline after 1 month (n = 10)	199 ± 10.2	145 ± 9.4	142 ± 9.9	38.5 ± 0.7
	191 ± 9.8	139 ± 10.1	141 ± 8.7	39.1 ± 0.6
	P > 0.05	P > 0.05	P > 0.05	P > 0.05
WPL baseline after 1 month (n = 10)	209 ± 9.1	148 ± 14.5	159 ± 11.0	39.6 ± 1.2
	180 ± 8.0	97.5 ± 7.5	132 ± 7.8	44.5 ± 1.1
	P < 0.05*	P < 0.01*	P < 0.05*	P < 0.05*
Placebo baseline after 1 month (n = 10)	185 ± 10.3	135 ± 11.2	146 ± 12.4	40.1 ± 1.0
	182 ± 9.6	141 ± 10.5	144 ± 11.7	40.6 ± 0.9
	P > 0.05	P > 0.05	P > 0.05	P > 0.05